<DOC>
	<DOCNO>NCT00454779</DOCNO>
	<brief_summary>This randomize , open-label , 2-arm , control , phase 2 , multi-center , estimation clinical trial docetaxel cisplatin combination chemotherapy without panitumumab first-line treatment subject metastatic recurrent head neck cancer , well cross-over second-line panitumumab monotherapy subject fail chemotherapy arm . This study conduct United States . Approximately 150 subject histologically cytologically confirm metastatic and/or recurrent SCCHN .</brief_summary>
	<brief_title>PARTNER : Panitumumab Added Regimen Treatment Head aNd Neck Cancer Evaluation Response</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically cytologically confirm metastatic and/or recurrent Squamous Cell Carcinoma Head Neck ( SCCHN ) determine incurable surgery and/or radiation therapy . Measurable disease CT scan Eastern Cooperative Oncology Group ( ECOG ) performance score 0 1 Age : 18 year old Adequate hematologic , renal , metabolic , hepatic &amp; thyroid function Prior systemic treatment metastatic and/or recurrent SCCHN CNS metastasis , nasopharyngeal carcinoma History interstitial lung disease History another primary cancer Any comorbid disease would increase risk toxicity Active infection require systemic treatment Prior antiEpidermal Growth Factor receptor ( antiEGFr ) antibody therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>SCCHNC</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Recurrent</keyword>
</DOC>